Xeris Biopharma Holdings

Rising Healthcare Costs And Regulation Will Erode Margins

AnalystLowTarget

Not Invested

Community Contributor

Published

28 Aug 25

AnalystLowTarget's Fair Value

US$6.00

36.5% overvalued

04 Sep

US$8.19

194.6%

-1.4%

194.6%

-1.4%

You can edit this narrative until Aug 28 10:20 PM. Then, changes will post as Updates.

Author's Valuation

US$636.5% overvalued

AnalystLowTarget Fair Value

Narrative

Updates0

AnalystLowTarget Fair Value

US$6

36.5% overvalued

Future estimation in

% p.a.

Decrease

Increase

Current revenue growth rate

17.23%

Pharma revenue growth rate

0.66%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

6.78%

Calculation

US$21.39m

Earnings '28

67.26x

PE Ratio '28

US$1.44b

Market Cap '28

US$1.44b

Market Cap '28

197.82m

No. shares '28

US$7.27

Share Price '28

US$7.27 Share Price '28

Discounted to 2025 @ 6.78% p.a.

US$5.98

Fair Value '25